When researchers graded the evidence behind photobiomodulation across 35 different health outcomes, fibromyalgia fatigue landed in the small group that came out strongest — and the authors name fibromyalgia first among the conditions with the best support.
That is worth sitting with, because fatigue usually has the weakest evidence behind any given treatment.
What the review did
A 2025 umbrella review published in Systematic Reviews set out to assess photobiomodulation across everything it had been properly studied for, rather than one condition at a time. It pooled 15 meta-analyses covering 204 randomised controlled trials and more than 9,000 participants, spanning 35 health endpoints across 15 conditions.
Then it did the part that makes it useful: it graded the certainty of the evidence behind each endpoint using a modified GRADE framework, rather than simply reporting whichever effects reached statistical significance.
What it found
Twelve outcomes showed significant effects. Five of those were supported by moderate-certainty evidence — the highest grade anything in the review reached — and fibromyalgia fatigue was one of them, at an equivalent standardised mean difference of 1.25 (95% CI 0.63 to 1.87).
The other four moderate-certainty findings were burning mouth syndrome pain, knee osteoarthritis disability, androgenetic alopecia hair density, and cognitive function. Hair density carried the largest estimate at 1.32, with fibromyalgia fatigue next at 1.25 — a small cluster of findings that held up under strict grading, not one isolated result.
Five out of 35 cuts both ways: the review was strict, and fibromyalgia fatigue is in the small group that survived it.
The precision that belongs with it
Most of the other endpoints in the review were graded low or very low certainty, largely because of heterogeneity between trials and small-study effects. The authors’ own conclusion is that further high-quality trials and standardisation of treatment protocols are warranted before widespread clinical adoption.
So this is an adjunct with modest, real effects in the conditions where it has been studied properly. In fibromyalgia it sits alongside the things that do the durable work — graded activity within a sustainable envelope, sleep, and whatever medical management your own physician has in place — rather than replacing any of them. We are not citing a device clearance for this use, and a group average in a pooled analysis is not a prediction about any individual.
Why we tell patients about the grading and not just the number
Because the grade tells you how much weight to put on the number.
An effect size with moderate-certainty evidence behind it and an identical one with very-low-certainty evidence look the same in a headline and mean quite different things in a clinic. A review that reports both, and says which is which, is why we can point at this finding with some confidence while being straightforward about the rest.
If you have fibromyalgia and fatigue is your dominant symptom, this is a reasonable thing to ask about. It is also reasonable to ask what else is being done at the same time, because on its own it is not a plan.
This article is general education, not medical advice, and it is not a substitute for evaluation by a qualified clinician. It does not establish a physician–patient relationship. Individual results vary, and the studies described report group averages rather than what any one person should expect. Treatments discussed may not be FDA-cleared or approved for the conditions mentioned; where that is the case it is stated in the text. Talk to your own physician before starting, stopping or changing any treatment.
Son 2025 — PMID 40770824
